UK Markets close in 3 hrs 10 mins

Bionano Genomics, Inc. (0A4K.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.8950-0.2200 (-10.40%)
As of 06:28PM GMT. Market open.

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600

Full-time employees147

Key executives

NameTitlePayExercisedYear born
Dr. Robert Erik HolmlinPres, CEO, Sec. & Director519.07kN/A1968
Mr. Christopher P. StewartChief Financial Officer77.93kN/A1970
Mr. Mark OldakowskiChief Operating Officer376.1kN/A1974
Dr. Alka Chaubey FACMG, Ph.D.Chief Medical OfficerN/AN/A1973
Mr. Robert J. PriarChief Commercial OfficerN/AN/AN/A
Mr. Richard ShippyChief Bus. OfficerN/AN/AN/A
Dr. Soheil Shams Ph.D.Chief Informatics OfficerN/AN/AN/A
Mark AdamchakControllerN/AN/AN/A
Dr. Paul R. Selvin Ph.D.Scientific AdvisorN/AN/AN/A
Prof. Pui-Yan Kwok M.D., Ph.D.Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Its Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables scientists and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. The company also provides diagnostic testing for those with autism spectrum disorder and other neurodevelopmental disabilities. In addition, it offers an agnostic cross-platform data interpretation and clinical reporting software that integrates next-generation sequencing and microarray data, and provides visualization of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome for a fully integrated analysis in one view. The company was founded in 2006 and is headquartered in San Diego, California.

Corporate governance

Bionano Genomics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.